medi3617
Showing 1 - 2 of 2
Metastatic Melanoma Trial in Boston (Tremelimumab, MEDI3617)
Active, not recruiting
- Metastatic Melanoma
- Tremelimumab
- MEDI3617
-
Boston, Massachusetts
- +1 more
Mar 22, 2022
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors Trial in United States (MEDI3617, Bevacizumab, Paclitaxel)
Completed
- Advanced Solid Tumors
- Advanced Recurrent Ovarian Tumors
- MEDI3617
- +3 more
-
Los Angeles, California
- +9 more
Feb 9, 2017